COVID-19 and hypopituitarism

[1]  G. Balercia,et al.  “Mask up to keep it up”: Preliminary evidence of the association between erectile dysfunction and COVID‐19 , 2021, The Journal of Sexual Medicine.

[2]  A. Salonia,et al.  Low testosterone levels predict clinical adverse outcomes in SARS‐CoV‐2 pneumonia patients , 2020, The Journal of Sexual Medicine.

[3]  A. Vaidya,et al.  The Impact of the COVID-19 Pandemic on Self-Reported Outcomes in Patients With Adrenal Insufficiency , 2021, The Journal of clinical endocrinology and metabolism.

[4]  E. Bosi,et al.  Weight trajectories and abdominal adiposity in COVID-19 survivors with overweight/obesity , 2021, International Journal of Obesity.

[5]  A. Giustina,et al.  COVID-19 and the pituitary , 2021, Pituitary.

[6]  M. Puig-Domingo,et al.  COVID-19 and endocrine and metabolic diseases. An updated statement from the European Society of Endocrinology , 2021, Endocrine.

[7]  S. O’Rahilly,et al.  Associations between body-mass index and COVID-19 severity in 6·9 million people in England: a prospective, community-based, cohort study , 2021, The Lancet Diabetes & Endocrinology.

[8]  G. Ippolito,et al.  Effects of SARS-CoV-2 on Cardiovascular System: The Dual Role of Angiotensin-Converting Enzyme 2 (ACE2) as the Virus Receptor and Homeostasis Regulator-Review , 2021, International journal of molecular sciences.

[9]  Marcos Lima-Martínez,et al.  COVID-19 and diabetes: A bidirectional relationship , 2020, Clínica e Investigación en Arteriosclerosis (English Edition).

[10]  Gregory F. Wu,et al.  Glucocorticoids and B Cell Depleting Agents Substantially Impair Immunogenicity of mRNA Vaccines to SARS-CoV-2 , 2021, medRxiv.

[11]  L. Pannone,et al.  Role of comorbidities on the mortality in patients with SARS-CoV-2 infection: an Italian cohort study. , 2021, Minerva medica.

[12]  I. Benedek,et al.  Systemic Inflammation and COVID-19 Mortality in Patients with Major Noncommunicable Diseases: Chronic Coronary Syndromes, Diabetes and Obesity , 2021, Journal of clinical medicine.

[13]  R. Flores-Mejía,et al.  Impact of Metabolic Syndrome in the Clinical Outcome of Disease by SARS-COV-2 , 2021, Archives of Medical Research.

[14]  A. Gavazzi,et al.  Covid-19 and gender: lower rate but same mortality of severe disease in women—an observational study , 2021, BMC Pulmonary Medicine.

[15]  S. Grottoli,et al.  Traumatic Brain Injury as Frequent Cause of Hypopituitarism and Growth Hormone Deficiency: Epidemiology, Diagnosis, and Treatment , 2021, Frontiers in Endocrinology.

[16]  M. Fleseriu.  Pituitary Disorders and COVID-19, Reimagining Care: The Pandemic A Year and Counting , 2021, Frontiers in Endocrinology.

[17]  M. Gadelha,et al.  Glucocorticoid use in patients with adrenal insufficiency following administration of the COVID-19 vaccine: a pituitary society statement , 2021, Pituitary.

[18]  Wei Yang,et al.  A Comparison of Methylprednisolone and Dexamethasone in Intensive Care Patients With COVID-19 , 2021, medRxiv.

[19]  Stephen J Bordes,et al.  Pituitary Apoplexy Attributed to COVID-19 Infection in the Absence of an Underlying Macroadenoma or Other Identifiable Cause , 2021, Cureus.

[20]  R. Bertolo,et al.  Anosmia and ageusia: a piece of the puzzle in the etiology of COVID-19-related transitory erectile dysfunction , 2021, Journal of Endocrinological Investigation.

[21]  A. Formenti,et al.  Effects of Medical Treatment of Prostate Cancer on Bone Health , 2021, Trends in Endocrinology & Metabolism.

[22]  M. Aarabi,et al.  Pathophysiological Clues to How the Emergent SARS-CoV-2 Can Potentially Increase the Susceptibility to Neurodegeneration , 2021, Molecular Neurobiology.

[23]  J. Benito-León,et al.  A Rare Case of SARS-CoV-2 Infection Associated With Pituitary Apoplexy Without Comorbidities , 2021, Journal of the Endocrine Society.

[24]  N. Javed,et al.  Diabetes Insipidus and Concomitant Myocarditis: A Late Sequelae of COVID-19 Infection , 2021, Journal of investigative medicine high impact case reports.

[25]  J. Mascola,et al.  Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine , 2020, The New England journal of medicine.

[26]  Jue Wang,et al.  Dexamethasone inhibits SARS-CoV-2 spike pseudotyped virus viropexis by binding to ACE2 , 2020, Virology.

[27]  E. Alqahtani,et al.  The Impact of COVID-19 Viral Infection on the Hypothalamic-Pituitary-Adrenal Axis , 2020, Endocrine Practice.

[28]  ESC / EAS Guidelines for the Treatment of Dyslipidemias: Lipid Modification to Reduce Cardiovascular Risk , 2020, Digital Doctor.

[29]  P. Dormitzer,et al.  Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine , 2020, The New England journal of medicine.

[30]  H. Marcus,et al.  The direct and indirect impact of the COVID-19 pandemic on the care of patients with pituitary disease: a cross sectional study , 2020, Pituitary.

[31]  H. Schiöth,et al.  Sex differences in COVID-19: the role of androgens in disease severity and progression , 2020, Endocrine.

[32]  A. Formenti,et al.  Radiological Thoracic Vertebral Fractures are Highly Prevalent in COVID-19 and Predict Disease Outcomes , 2020, The Journal of clinical endocrinology and metabolism.

[33]  M. Contreras,et al.  COVID-19 y diabetes mellitus: una relación bidireccional , 2020, Clinica E Investigacion En Arteriosclerosis.

[34]  Z. Khan,et al.  DIABETES INSIPIDUS AS A SYMPTOM OF COVID-19 INFECTION: CASE REPORT , 2020, Chest.

[35]  Yan-Mei Huang,et al.  Obesity in patients with COVID-19: a systematic review and meta-analysis , 2020, Metabolism.

[36]  C. A. Almendárez-Sánchez,et al.  Pituitary macroadenoma apoplexy in a severe acute respiratory syndrome-coronavirus-2-positive testing: Causal or casual? , 2020, Surgical neurology international.

[37]  M. Brandi,et al.  Sexual Dimorphism of Coronavirus 19 Morbidity and Lethality , 2020, Trends in endocrinology and metabolism.

[38]  A. Mamelak,et al.  Pituitary apoplexy associated with acute COVID-19 infection and pregnancy , 2020, Pituitary.

[39]  C. Scaroni,et al.  Practical Considerations for the Management of Cushing's Disease and COVID-19: A Case Report , 2020, Frontiers in Endocrinology.

[40]  G. Arnaldi,et al.  Impact of COVID-19 pandemic on psychophysical stress in patients with adrenal insufficiency: the CORTI-COVID study , 2020, Journal of Endocrinological Investigation.

[41]  A. Giustina,et al.  COVID-19 and hypopituitarism. Experience from an endocrine center in a high-impact area , 2020 .

[42]  Mikiko Watanabe,et al.  Is Growth Hormone Insufficiency the Missing Link Between Obesity, Male Gender, Age, and COVID‐19 Severity? , 2020, Obesity.

[43]  Jia Gu,et al.  Analysis of 2019-nCoV receptor ACE2 expression in different tissues and its significance study , 2020, Annals of translational medicine.

[44]  E. Christ,et al.  Excess Mortality Among Hospitalized Patients with Hypopituitarism - A Population Based Matched Cohort Study. , 2020, The Journal of clinical endocrinology and metabolism.

[45]  L. Ghiadoni,et al.  Hyperglycemia at Hospital Admission Is Associated With Severity of the Prognosis in Patients Hospitalized for COVID-19: The Pisa COVID-19 Study , 2020, Diabetes Care.

[46]  D. Accili,et al.  MECHANISMS IN ENDOCRINOLOGY: Vitamin D and COVID-19 , 2020, European journal of endocrinology.

[47]  Yangang Wang,et al.  Comorbidities and the risk of severe or fatal outcomes associated with coronavirus disease 2019: A systematic review and meta-analysis , 2020, International Journal of Infectious Diseases.

[48]  S. Del Prato,et al.  COVID-19 in people with diabetes: understanding the reasons for worse outcomes , 2020, The Lancet Diabetes & Endocrinology.

[49]  F. Casanueva,et al.  Pituitary Tumors Centers of Excellence. , 2020, Endocrinology and metabolism clinics of North America.

[50]  M. Puig-Domingo,et al.  Endocrine and metabolic aspects of the COVID-19 pandemic , 2020, Reviews in Endocrine and Metabolic Disorders.

[51]  H. Krumholz,et al.  Extrapulmonary manifestations of COVID-19 , 2020, Nature Medicine.

[52]  M. Arosio,et al.  Growth hormone therapy at the time of Covid-19 pandemic: adherence and drug supply issues , 2020, European journal of endocrinology.

[53]  H. Marcus,et al.  Pituitary society guidance: pituitary disease management and patient care recommendations during the COVID-19 pandemic—an international perspective , 2020, Pituitary.

[54]  V. Morelli,et al.  Adrenal Insufficiency at the Time of COVID-19: A Retrospective Study in Patients Referring to a Tertiary Center , 2020, The Journal of clinical endocrinology and metabolism.

[55]  S. Hadjadj,et al.  Phenotypic characteristics and prognosis of inpatients with COVID-19 and diabetes: the CORONADO study , 2020, Diabetologia.

[56]  J. Shapiro,et al.  Androgenetic alopecia present in the majority of patients hospitalized with COVID-19: The “Gabrin sign” , 2020, Journal of the American Academy of Dermatology.

[57]  F. Chigr,et al.  Autonomic Brain Centers and Pathophysiology of COVID-19 , 2020, ACS chemical neuroscience.

[58]  I. D. Q. Marzola,et al.  Neurotropism of SARS-CoV 2: Mechanisms and manifestations , 2020, Journal of the Neurological Sciences.

[59]  T. Renné,et al.  Sex hormone and metabolic dysregulations are associated with critical illness in male Covid-19 patients , 2020 .

[60]  M. Rugge,et al.  Androgen-deprivation therapies for prostate cancer and risk of infection by SARS-CoV-2: a population-based study (N = 4532) , 2020, Annals of Oncology.

[61]  O. Dekkers,et al.  Endocrinology in the time of COVID-19: Management of pituitary tumours , 2020, European journal of endocrinology.

[62]  G. Arnaldi,et al.  COVID-19 infection and glucocorticoids: update from the Italian Society of Endocrinology Expert Opinion on steroid replacement in adrenal insufficiency , 2020, Journal of Endocrinological Investigation.

[63]  E. Hoorn,et al.  ENDOCRINOLOGY IN THE TIME OF COVID-19: Management of diabetes insipidus and hyponatraemia , 2020, European Journal of Endocrinology.

[64]  J. Shapiro,et al.  A preliminary observation: Male pattern hair loss among hospitalized COVID‐19 patients in Spain – A potential clue to the role of androgens in COVID‐19 severity , 2020, Journal of cosmetic dermatology.

[65]  L. Mao,et al.  Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China. , 2020, JAMA neurology.

[66]  D. Mathieu,et al.  High Prevalence of Obesity in Severe Acute Respiratory Syndrome Coronavirus‐2 (SARS‐CoV‐2) Requiring Invasive Mechanical Ventilation , 2020, Obesity.

[67]  G. Mazziotti,et al.  Secondary hyperparathyroidism and thoracic vertebral fractures in heart failure middle-aged patients: a 3-year prospective study , 2020, Journal of Endocrinological Investigation.

[68]  S. Pearce,et al.  ENDOCRINOLOGY IN THE TIME OF COVID-19: Management of adrenal insufficiency , 2020, European journal of endocrinology.

[69]  L. Vaira,et al.  Anosmia and Ageusia: Common Findings in COVID‐19 Patients , 2020, The Laryngoscope.

[70]  M. Puig-Domingo,et al.  COVID-19 and endocrine diseases. A statement from the European Society of Endocrinology , 2020, Endocrine.

[71]  Xin Zhou,et al.  Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China , 2020, The Journal of Emergency Medicine.

[72]  A. Walls,et al.  Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein , 2020, Cell.

[73]  M. Maggi,et al.  Erectile dysfunction and cardiovascular risk: a review of current findings , 2020, Expert review of cardiovascular therapy.

[74]  L. Kurnutala,et al.  Pituitary tumor resection in a patient with SARS-CoV-2 (COVID-19) infection. A case report and suggested airway management guidelines , 2020, Brazilian Journal of Anesthesiology (English Edition).

[75]  John Watkins,et al.  Preventing a covid-19 pandemic , 2020, BMJ.

[76]  Ting Yu,et al.  Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study , 2020, The Lancet.

[77]  Ho‐Seong Han,et al.  Critical appraisal of definitions and diagnostic criteria for sarcopenic obesity based on a systematic review. , 2019, Clinical nutrition.

[78]  M. Christ-Crain,et al.  Association of adrenal insufficiency with patient-oriented health-care outcomes in adult medical inpatients , 2019, European journal of endocrinology.

[79]  D. Kelly,et al.  Pituitary Apoplexy. , 2019, Neurosurgery clinics of North America.

[80]  K. Toulis,et al.  Increased Infection Risk in Addison’s Disease and Congenital Adrenal Hyperplasia , 2019, The Journal of clinical endocrinology and metabolism.

[81]  M. Sabatine,et al.  2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. , 2019, European heart journal.

[82]  Shiro Tanaka,et al.  Impact of underlying chronic adrenal insufficiency on clinical course of hospitalized patients with adrenal crisis: A nationwide cohort study. , 2019, European journal of internal medicine.

[83]  E. van Nood,et al.  Hypopituitarism after Orthohantavirus Infection: What is Currently Known? , 2019, Viruses.

[84]  J. Wit,et al.  Effect of adherence to growth hormone treatment on 0–2 year catch-up growth in children with growth hormone deficiency , 2018, PloS one.

[85]  G. Mazziotti,et al.  Pituitary Diseases and Bone , 2018, Endocrine reviews.

[86]  Jae Hyuk Lee,et al.  Risk of Pneumonia After Vertebral Compression Fracture in Women With Low Bone Density: A Population-Based Study , 2018, Spine.

[87]  R. Murray,et al.  Mortality data from the European Adrenal Insufficiency Registry—Patient characterization and associations , 2018, Clinical endocrinology.

[88]  J. Wass,et al.  SOCIETY FOR ENDOCRINOLOGY CLINICAL GUIDANCE: Inpatient management of cranial diabetes insipidus , 2018, Endocrine connections.

[89]  A. Luger,et al.  The prevalence of the metabolic syndrome and associated cardiovascular complications in adult-onset GHD during GH replacement: a KIMS analysis , 2018, Endocrine connections.

[90]  M. Saito,et al.  Restrictive pulmonary dysfunction is associated with vertebral fractures and bone loss in elderly postmenopausal women , 2018, Osteoporosis International.

[91]  A. Formenti,et al.  MANAGEMENT OF ENDOCRINE DISEASE: Risk of overtreatment in patients with adrenal insufficiency: current and emerging aspects. , 2017, European journal of endocrinology.

[92]  M. Maghnie,et al.  PREVALENCE AND CORRELATES OF ADHERENCE IN CHILDREN AND ADOLESCENTS TREATED WITH GROWTH HORMONE: A MULTICENTER ITALIAN STUDY. , 2017, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[93]  A. Formenti,et al.  Diabetes in Cushing Disease , 2017, Current Diabetes Reports.

[94]  J. Lord,et al.  Primary adrenal insufficiency is associated with impaired natural killer cell function: a potential link to increased mortality , 2017, European journal of endocrinology.

[95]  M. Murad,et al.  Hormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice Guideline. , 2016, The Journal of clinical endocrinology and metabolism.

[96]  G. Johannsson,et al.  Exploring Inpatient Hospitalizations and Morbidity in Patients With Adrenal Insufficiency. , 2016, The Journal of clinical endocrinology and metabolism.

[97]  A. Formenti,et al.  Growth hormone receptor isoforms and fracture risk in adult‐onset growth hormone‐deficient patients , 2016, Clinical endocrinology.

[98]  G. Mazziotti,et al.  Current and Emerging Aspects of Diabetes Mellitus in Acromegaly , 2016, Trends in Endocrinology & Metabolism.

[99]  J. Pedro-Botet,et al.  Erectile dysfunction and cardiovascular risk factors in a Mediterranean diet cohort , 2016, Internal medicine journal.

[100]  G. Mazziotti,et al.  Incidence of morphometric vertebral fractures in adult patients with growth hormone deficiency , 2016, Endocrine.

[101]  H. Genant,et al.  Relationship Between Vertebral Fracture Burden, Height Loss, and Pulmonary Function in Postmenopausal Women With Osteoporosis. , 2015, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.

[102]  P. Chanson,et al.  Pituitary Apoplexy. , 2015, Endocrine reviews.

[103]  F. Doglietto,et al.  New oral anticoagulants and pituitary apoplexy , 2016, Pituitary.

[104]  R. Dalan,et al.  Pituitary apoplexy secondary to thrombocytopenia due to dengue hemorrhagic fever: a case report and review of the literature. , 2014, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[105]  C. Gazzaruso,et al.  Cardiovascular risk in adult patients with growth hormone (GH) deficiency and following substitution with GH--an update. , 2014, The Journal of clinical endocrinology and metabolism.

[106]  M. Stojanović,et al.  Growth hormone replacement normalizes impaired fibrinolysis: new insights into endothelial dysfunction in patients with hypopituitarism and growth hormone deficiency. , 2013, Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society.

[107]  E. Erfurth.  Update in mortality in GH-treated patients. , 2013, The Journal of clinical endocrinology and metabolism.

[108]  G. Mazziotti,et al.  Prevalence of thoracic vertebral fractures in hospitalized elderly patients with heart failure. , 2012, European journal of endocrinology.

[109]  M. Heymans,et al.  Does growth hormone replacement therapy reduce mortality in adults with growth hormone deficiency? Data from the Dutch National Registry of Growth Hormone Treatment in adults. , 2011, The Journal of clinical endocrinology and metabolism.

[110]  B. Souweine,et al.  Association between hypernatraemia acquired in the ICU and mortality: a cohort study. , 2010, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[111]  Niels Møller,et al.  Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects. , 2009, Endocrine reviews.

[112]  F. Casanueva,et al.  Hyperprolactinemia and prolactinomas. , 2008, Endocrinology and metabolism clinics of North America.

[113]  P. Laurberg,et al.  Excess mortality in women with pituitary disease: a meta‐analysis , 2007, Clinical endocrinology.

[114]  G. Mazziotti,et al.  Growth hormone deficiency in the adult , 2006, Pituitary.

[115]  P. Cappabianca,et al.  Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas , 2006, Clinical endocrinology.

[116]  M. Leow,et al.  Hypocortisolism in survivors of severe acute respiratory syndrome (SARS) , 2005, Clinical endocrinology.

[117]  A. Giustina,et al.  Clinical review: Growth hormone and cardiovascular risk factors. , 2005, The Journal of clinical endocrinology and metabolism.

[118]  C. Meazza,et al.  Effect of growth hormone (GH) on the immune system. , 2004, Pediatric endocrinology reviews : PER.

[119]  Qingling Zhang,et al.  Organ distribution of severe acute respiratory syndrome (SARS) associated coronavirus (SARS‐CoV) in SARS patients: implications for pathogenesis and virus transmission pathways , 2004, The Journal of pathology.

[120]  G. Navis,et al.  Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis , 2004, The Journal of pathology.

[121]  R. Napoli,et al.  Acute effects of growth hormone on vascular function in human subjects. , 2003, The Journal of clinical endocrinology and metabolism.

[122]  R. Clayton,et al.  Coronary risk in growth hormone deficient hypopituitary adults: increased predicted risk is due largely to lipid profile abnormalities , 2001, Clinical endocrinology.

[123]  N. Rifai,et al.  Effects of Growth Hormone Administration on Inflammatory and Other Cardiovascular Risk Markers in Men with Growth Hormone Deficiency , 2000, Annals of Internal Medicine.

[124]  N. Rifai,et al.  Effects of growth hormone administration on inflammatory and other cardiovascular risk markers in men with growth hormone deficiency. A randomized, controlled clinical trial. , 2000, Annals of internal medicine.

[125]  E. Carter,et al.  Effect of prednisone on response to influenza virus vaccine in asthmatic children. , 1998, Archives of pediatrics & adolescent medicine.

[126]  F. Follath,et al.  Acute cardiovascular effects of insulin-like growth factor I in patients with chronic heart failure. , 1998, The Journal of clinical endocrinology and metabolism.

[127]  G. Brabant,et al.  Nitric oxide may mediate the hemodynamic effects of recombinant growth hormone in patients with acquired growth hormone deficiency. A double-blind, placebo-controlled study. , 1996, The Journal of clinical investigation.

[128]  P. Lips,et al.  Histomorphometric analysis of bone mass and bone metabolism in growth hormone deficient adult men. , 1996, Bone.

[129]  B. Bengtsson,et al.  Growth hormone-deficient adults are insulin-resistant. , 1995, Metabolism: clinical and experimental.

[130]  B. Bengtsson,et al.  Effects of treatment with recombinant human growth hormone on insulin sensitivity and glucose metabolism in adults with growth hormone deficiency. , 1993, Metabolism: clinical and experimental.

[131]  L. Wilhelmsen,et al.  Cardiovascular risk factors in adult patients with growth hormone deficiency. , 1993, Acta endocrinologica.

[132]  P. Sönksen,et al.  The effects of treatment with recombinant human growth hormone on body composition and metabolism in adults with growth hormone deficiency. , 1989, The New England journal of medicine.

[133]  J Otradovec,et al.  [Pituitary apoplexy]. , 1972, Ceskoslovenska oftalmologie.